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Abstract: Conventional chemotherapy is the most common therapeutic method for treating cancer by
the application of small toxic molecules thatinteract with DNA and causecell death. Unfortunately,
these chemotherapeutic agents are non-selective and can damage both cancer and healthy tissues,
producing diverse side effects, andthey can have a short circulation half-life and limited targeting.
Many synthetic polymers have found application as nanocarriers of intelligent drug delivery systems
(DDSs). Their unique physicochemical properties allow them to carry drugs with high efficiency,
specificallytarget cancer tissue and control drug release. In recent years, considerable efforts have
been made to design smart nanoplatforms, including amphiphilic block copolymers, polymer-drug
conjugates and in particular pH- and redox-stimuli-responsive nanoparticles (NPs). This review
is focused on a new generation of polymer-based DDSs with specific chemical functionalities that
improve their hydrophilicity, drug loading and cellular interactions.Recentlydesigned multifunctional
DDSs used in cancer therapy are highlighted in this review.
Keywords: block copolymers; polymer-drug conjugates; polymeric nanocarriers; cancer therapy
1. Introduction
After cardiovascular diseases, cancer is the second leading cause of death worldwide [1].
Conventional chemotherapy is the most commonly used approach in cancer treatment, along
with surgery, irradiation and immunotherapy [2]. It is based on the application of small toxic
chemotherapeutic molecules that interact with DNA molecules, modify them and induce cell death in
cancer tissues [3,4]. Cancer cells have altered lipid and amino acid metabolic pathways, glycolysis,
and redox homeostasis [1,5]. Indeed, altered energy metabolism with upregulated glucose transporter
expression, disrupted redox homeostasis with upregulated glutathione transferase (GST) and high
telomerase activityare responses that maintain DNA integrity, retaining replication, proliferation
and cancer cell resistance [1,5,6]. Chemotherapy has many disadvantages, including drug toxicity,
rapid degradation, low specificity and limited targeting. In the last few decades, nanomedicine has
assumed an important role in cancer therapy based on diverse tailor-made drug delivery systems
(DDSs) [7]. Nanomedicine produces materials with sizes ranging from 1–100 nm, which are used
as drug nanocarriers with exceptional properties, such as their size, solubility, hydrophilicity, high
specificity and a suitable drug-release profile. Nanocarriers also have an enhanced permeability and
retention effect (EPR) due to their accumulation in cancer tissue with leaky vasculature [8].
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Chemotherapeutics are mostly drugs that are poorly soluble in water with a limited delivery
to the target tissue. Encapsulation or entrapment of drugs in nanocarriers facilitates their transport
in the circulation to the cancer tissue, inhibiting their rapid biodegradation and improving their
bioavailability [9]. Moreover, nanocarriers with incorporated drugs provide a longer circulation
half-life of drugs, increasing their efficacy and enabling a lower dose of application [2,9]. Compared
with natural polymers, synthetic nanocarriers can be tailored to control the release of encapsulated drugs
by modifying their structure [10]. This review is focused on currently obtained polymer-based DDSsand
it examines the challenges in improving their drug delivery properties through the introduction of
targeting and stimuli-response moieties. Polymer-based drug delivery systems and polymer-drug
conjugates used in cancer therapy are summarized, as well as the underlying structure responsible for
the efficacy of these nanodevices.
2. Polymeric Nanoparticles (NPs)
Polymeric NPs are particles obtained from natural, semi-synthetic or synthetic polymers. Polymeric
nanosystems are produced by a polymerization reaction of many monomer units, and under certain
conditions, they can be organized and self-assemble with ananometric size (10–100 nm) [10–12]. Due
to the high diversity of their properties, NPs attract great attention as multifunctional nanocarriers in
DDSs [9,11]
Depending on the preparation method, drugs can be entrapped, encapsulated or bound to
polymeric NPs in the form of a nanosphere, a nanocapsule or a drug conjugate (Figure 1) [7,9,10].
Nanospheres are colloidal particles that entrap the drug inside their matrix by physical dispersion or
by adsorption on the particle surface, while nanocapsules are systems consisting of a core cavity with
an encapsulated drug and polymeric shell surrounding it. Polymeric capsules can be designed by the
conjugation of targeting ligands that increase selectivity for cancer cells and improve intracellular drug
delivery, as well as reducing different side effects and drug toxicity. Targeting ligands of polymeric
capsules are commonly monoclonal antibodies (mAbs) or antibody fragments, aptamers, peptides and
small molecules, such as folic acid, which are conjugated to the shell-forming block [13–19]. These
ligands are specifically bound to antigens or receptors that are overexpressed on the cancer cell [20]
and they enable cellular selectivity and intracellular delivery of polymeric micelles [13]. Different
designed polymeric capsules suitable for targeting the release of drugs are shown in Figure 1. The
efficacy of polymeric carriers modified with targeting ligands depends on the ligand properties, such
as their density and binding affinities to receptors, which can enhance receptor internalization and
the biodistribution of drugs. Drug-conjugates have a drug that is chemically bonded to the polymer
through a linker/spacer. The bond drug-linker/spacer is a common breakage-point when the drug is
released at the target site (Figure 1).
Natural polymers are biopolymers, including different classes of polysaccharides and proteins,
which, due to their biocompatibility and biodegradability, are particularly suitable for medical
applications, as in cell-based transplantation, tissue engineering and gene therapy [10] (Figure 2).
Natural polymers can be combined with synthetic molecules through the chemical modification of
their functional groups and so-called semi-synthetic polymers can mimic human tissue components.
In formulations of controlled DDSs, synthetic polymers attract more attention than biopolymers due to
the considerable potential for the design of their structure and modifications of their physicochemical
properties (Figure 2) [8]. Synthetic polymeric micelles exhibita high capacityto incorporate a broad range
of bioactive molecules, such as antisense oligonucleotides [21], plasmid DNA [22], proteins [23], small
interfering ribonucleic acids (siRNAs) [24], messenger RNAs (mRNAs) [25] and photosensitizers [26],
by tailoring the core-forming segments of the block copolymers. In fact, several poly-ion complex
(PIC) micelles have been designed that incorporate negatively charged biomolecules by electrostatic
interaction with positively charged block copolymers [21,27]. In addition, they can be stabilized by
the covalent crosslinking of their core through disulfide bonds [28], which can be cleaved under
specific intracellular conditions, enabling the complexes to escape from endosomal compartments after
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endocytosis and to deliver the biomolecules to subcellular destinations [29] without drug degradation.
By introducing hydrophobic molecules such as cholesterol to the core [30], PIC micelles become more
stable, with a longer half-life in the bloodstream, allowing for the delivery of intact biomolecules to
therapeutic targets. PIC micelles obtained from block copolymers with a core-forming polycation such
as polyaspartamides, support enhanced delivery of biomacromolecules to the cytosol of cells, and the
gene transfection in vitro and in vivo [25,29–35].
Figure 1. Schematic illustration of multifunctional drug delivery systems.
In recent years, the great potential of synthetic polymers as drug carriers has been highlighted,
particularly because of the possibility to develop DDSs with a target sustained/controlled release of
drugs [1]. The encapsulation of cancer drugs in polymeric micelles with modifications for cancer
targeting and triggered release results inmore efficient drug delivery (Figure 1).
In addition to biocompatibility and biodegradability, synthetic polymers used in DDSs should be
activated at the site of action, to be stable in blood circulation, to have low toxicity and immunogenicity,
and to provide protection fromthe degradation of drugs before the target tissue is reached. Additionally,
it is necessary that polymer nanocarriers of DDSscan be easily synthesized without impurities [8].
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Figure 2. Types of polymeric nanocarriers.
3. Amphiphilic Block Copolymers as Carriers in Drug Delivery Systems
3.1. Hydrophobic and Hydrophilic Polymeric Nanocarriers
Polymeric micelles are the most common nanocarriers of DDSs asregards the original core-shell
structure [8]. They consist of amphiphilic block copolymers with hydrophilic and hydrophobic units
that self-assemble in water solution at the critical micelle concentration (CMC). Micellar polymeric
units can be formed in different ways, such as diblock copolymers (A-B), triblock copolymers (A-B-A)
and copolymer conjugates (Figure 2) [9].
The hydrophobic core is suitable for encapsulating poorly water-soluble drugs, and the
pharmacokinetics of drug release can be controlled by its modification. The most frequently used
hydrophobic polymers for core formation of NPs are: poly(ε-caprolactone) (PCL), poly(lactic acid)
(PLA), poly(lactic-co-glycolic acid) (PLGA), poly(propylene oxide) (PPO) and poly(aspartic acid) (PAsp)
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(Figure 2). The hydrophilic polymers that are most frequently considered for the hydrophilic shell of
NPs in DDS include poly(ethylene glycol) (PEG), poly(glutamic acid) (PGA), poly(ethyleneimine) (PEI),
N-(2-hydroxypropyl)methacrylamide (HPMA) and poly(acrylamide) (PAM) (Figure 2). A frequently
used hydrophilic polymer of DDSs is PEG, which providesdistinctstability to NPs due to the reduction
of nonspecific interactions with blood proteins, thus preventing their aggregation [36].
3.2. Block Copolymers of DDSs in Cancer Therapy
Poly(ethylene glycol)-b-poly(ε-caprolactone)(PEG-PCL) is a polyether-polyester diblock copolymer,
synthesized by ring-opening polymerization of ε-caprolactone and PEG [37]. It is suitable for a variety
of DDSs because ofits high biocompatibility, biodegradability and low toxicity. Many DDSs based on
PEG-PCL with different hydrophilic/hydrophobic ratios (PEG/PCL) have been obtained, enablinghigher
cellular internalization byincreasingPEGcontribution(PEG/PCL = 5/5) [38]. Çırpanlı et al. have recently
developed PEG-PCL nanocarriers for the controlled delivery of camptothecin (CPT), whose active
lactone form was maintained by drug entrapment to hydrophobic PCL, preventing drug hydrolysis
in the carboxylate inactive form (Table 1) [39]. Furthermore, Hu et al.have designed a nanoplatform
with paclitaxel (PTX) encapsulated in a triblock PCL-PEG-PCL copolymer that in combination
with circadian chrono-modulated chemotherapy confirmed sustained drug release and a lower
cytotoxic effect compared with free PTX injection [40]. Hong et al. obtained image-guided polymeric
micelles, including a folate-conjugated PEG-b-PCL copolymer loaded with doxorubicin (DOX) and
superparamagnetic iron oxide nanoparticles (SPIONs) [41]. Active targeting was achieved by the
conjugation of folic acid to the PEG-b-PCL shell-forming block, allowing micelles to specifically bind
to receptors for folic acid that are overexpressed on the tumor cells. Drug-delivery efficiency and
diagnostics were considerably improved by the combination of active tumor targeting and imaging
in human hepatic carcinoma cells (Bel 7402 cells). Bel 7402 cells overexpress surface receptors for
folic acid that bind these folate-conjugated polymeric micelles, providing targeted delivery of DOX to
the cancer cells and exhibiting high inhibition of proliferation as compared to non-targeted micelles.
The epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein with an intracellular
tyrosine kinase domain, which is overexpressed on the cells of solid cancers [42]. Lee et al. developed
EGF-receptor-targeted PEG-b-PCL micelles with incorporated DOX and labeled with 111In. Images
were taken with micro-SPECT/CT intratumoral distribution of both targeted and non-targeted micelles
confirmedenhanced accumulation in tumor tissue with the targeted micelles (T-BCM) as compared to
non-targeted micelles (NT-BCM) [43].
Guo et al. have demonstratedthe suitability of the hydrophobic polymer PLGA to encapsulate
the low-solubility drug PTX in a poly(lactic-co-glycolic acid)-poly(ethylene glycol) (PLGA-PEG)
nanoplatform [44]. A longer circulation time and increased cancer inhibition were confirmed when
this DDS was decorated with DNA aptamersbecause of the enhanced cellular association of NPs in C6
glioma cells (Table 1) [44]. Recently, the Shafiei–Irannejadgroupdeveloped a poly(lactic-co-glycolic
acid)-d-α-tocopheryl polyethylene glycol 1000 succinate (PLGA-TPGS) nanodevice with two encapsulated
drugs, doxorubicin (DOX) and metformin (Met), which was shown to successfully inhibit the
P-glycoprotein efflux system through the combined effects of Met and TPGS.This DDSis mostly
used in the treatmentof multidrug-resistant breast cancer (Table 1) [45]. Examination of the outcome of
delivery of the combination of DOX and PCT applied in a polymeric system, PEG-PLGA, has attracted
attention due to the observed synergistic anticancer effect of drugs that achieved an improved/higher
therapeutic outcome. Wang et al. reported that methoxy PEG-PLGA NP co-loaded with hydrophilic
DOX and hydrophobic PCT possessed greater cancer growth inhibition than polymeric micelles loaded
with only one drug (either DOX or PCT), with the highest anticancer efficacy at a concentration ratio of
2:1 [46].Xu et al. also obtained an amphiphilic poly(ethylene glycol)-poly(L-lactic acid) (PEG-PLA)
diblock copolymer with incorporated DOX and PCT at a molar ratio of 1:1 in ultrafine PEG-PLA
fibers, using an “emulsion-electron spinning” method [47].These polymeric micelles revealed lower
cell viability and a higher percentage of cell-cycle arrest inrat glioma C6 cells 72 h after treatment.
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Moreover, Duong et al. also prepared a PEG-PLGA copolymer system for delivery of both DOX and
PCT, including targeting ligand folate (FOL) and TAT peptide, which enhances the cellular interaction
between PEG-PLGA micelles ina human oral cavity carcinoma KB cell line [48]. Essentially, FOL
increases the targeting ability of the drug carriers, while TAT peptide is a cell-penetrating peptide
(CPP) employed formodification of the carrier surface. Different concentration ratios of DOX and
PCT were applied in PEG-PLGA micelles, and higher effectiveness was reached at a concentration
ratio of 1:0.2 than at a concentration ratio of 1:1 [48]. The same ratio of drugs (1:0.2) was used in
the study by Lv et al. on a deoxycholate decorated methoxy poly(ethylene glycol)-b-poly(l-glutamic
acid)-b-poly(l-lysine) triblock system (mPEG-b-PLG-b-PLL) used for delivery of DOX and PCT, and
the synergistic effect of the drugs was confirmed [49]. Namely, the amphiphilic triblock copolymer
spontaneously self-assembled in a water solution into polymeric micelles, forming three different
domains with diverse functions: the outer hydrophilic PEG corona enabled extended circulation, the
middle hydrophilic PLG shell loaded DOX by electrostatic interactions, and the inner hydrophobic PLL
core incorporated PCT by hydrophobic interactions. Efficient tumor growth inhibition was obtained for
this co-delivery system in an A549 xenograft tumor model that caused 3.2-, 6.3-and 2.4-fold decreases in
tumor volume than when treated with free DOX, free PCT and free DOX + PCT, respectively. Theresults
obtained by studying the synergistic effect of DOX and PCT with various drug combinations suggest
that control of the applied amount of DOX is linked to its more rapid release than that of PCT; the
release of DOX facilitates the release of PCT, providing synergistic action.
A phase I study of the poly(ethylene glycol)-b-poly(glutamic acid) (PEG-PGlu) nanocarrier, which
consisted of a hydrophilic shell of PEG, a hydrophobic core of the derivative of PGlu and incorporated
drug cisplatin, has confirmed lower toxicity and completely different pharmacokinetics than those for
free cisplatin [50–52]. The clinical study of PEG-PGlu(Cisplatin) NPs in combination with gemcitabine
has entered phase III in patients with metastatic pancreatic cancer (Table 1) [52]. EGFR, known as a
transmembrane glycoprotein, that is overexpressed on the cells of solid cancers [42], is targeted with the
monoclonal antibody mAbC225. Vega et al. prepared mAb C225-based targeting PEG-b-PGlu micelles
with loaded DOXthat displayed a higher anticancer effect than free DOX, observed as inhibition of the
growth of A431 cells [53].
Table 1. Polymeric-anticancer drug nanoparticles (NPs), their loading mode and function.
Polymer Drug Loading Mode Function Reference
PEG-PCL Camptothecin (CPT) Entrapment Colon, breast, ovarian, lungand brain cancers [39]
PCL-PEG-PCL Paclitaxel (PTX) Encapsulation




PLGA-PEG Paclitaxel (PTX) Encapsulation Breast, pancreatic andovarian and brain cancers [44]
PLGA-TPGS Doxorubicin(DOX)-Metformin (Met) Encapsulation
Multidrug resistance P388
cancer cell lines [45]
PEG-PGlu Cisplatin Encapsulation Solid cancers [50–52]
mPEG-PLGA-PGlu Doxorubicin(DOX) Encapsulation Breast cancer [54]
PEG-PAsp Paclitaxel (PTX) Entrapment Advanced stomach cancer [55–57]
PEO-b-PAsp Doxorubicin Entrapment Pancreatic cancer [58]
PEO-PPO-PEO Doxorubicin. Encapsulation
Metastatic adenocarcinoma
of the esophagus and
gastroesophageal junction
[59,60]
PCLLA-PEG-PCLLA Doxorubicin (DOX) Encapsulation Breast cancer [61]
PEI-PLA Paclitaxel (PTX) Entrapment Lung cancer [62]








HPMA Doxorubicin (DOX) Copolymer-drugconjugation Lung and breast cancer [69,70]
HPMA Paclitaxel (PTX) Copolymer-drugconjugation Solid cancers [71]
HPMA Diaminocyclohexane(DACH)-platinum
Copolymer-drug
conjugation Solid cancer, ovarian cancer [72–75]
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DOX is a pro-apoptotic drug causing DNA damage and the activation of apoptosis [76] while
curcumin (CUR) is an antiangiogenic agent that blocks the transcription factor NF-jB, thus targeting
the MAPK and PI3K/PKB pathways and inhibiting protein kinase-C [77,78]. The co-delivery of
multiple drugs with the complementary anticancer mechanisms of nanocarriers offers an effective
strategy to treat cancer. To date, several NP formulations, such asmPEG-PCL micelles [79], poly(alkyl
cyanoacrylate) NPs [80] and PLLA NPs [81], have been obtained for the co-delivery of DOX and
CUR, although the majority of these NPs release the drug non-specifically, with a slow degradation
of the polymeric micelles. Co-encapsulation of DOX and CUR in pH-sensitive NPs has been shown
as a good strategy in treating cancer in a synergistic manner with increased efficacy and lower
toxicity by off-target exposure.The new synthesized triblock copolymer monomethoxy (polyethylene
glycol)-b-poly(D,L-lactic-co-glycolic acid)-b-poly(L-glutamic acid) (mPEG-PLGA-PGlu), including two
hydrophobic polymers, PGlu and PLGA, and the modified hydrophilic mPEG polymer, confirmed
possible encapsulation of CUR and DOX, with simultaneous targeting of heterogeneous breast cancer
cells (Table 1) [54]. These NPs are pH sensitive, and the PGlu segment incorporates DOX through
electrostatic interactions that alter the configuration in response to endosomal pH, while PLGA
encapsulates CUR inside the core through hydrophobic interactions. The loading efficiencies were
80.30% and 96.2% for CUR and DOX, respectively. A cascade of sustainedrelease, first of CUR followed
by a slower release of DOX, was shown at physiological pH.
The micellar PTX formulation PEG-PAsp, also known as NK105, consists of PEG and modified
polyaspartate as the hydrophobic block, with PTX incorporated via hydrophobic interactions. In
order to increase hydrophobicity and improve drug incorporation, half of the carboxylic groups of
the polyaspartate block were esterified with 4-phenyl-1-butanol after treatment with the condensing
agent 1,3-diisopropylcarbodiimide [55–57]. The paclitaxel (PCX) formulation of the poly(ethylene
glycol)-b-poly(aspartic acid) (PEG-PAsp) nanoplatform exhibited similar cytotoxicity in lung, gastric,
colon and ovarian cancers as the free drug, as well as higher resistance to allergic reactions in a phase I
clinical study [55–57].A phase II study is ongoing with patients with advanced stomach cancer (Table 1).
Vilar et al. reported a similar DOX formulation of an amphiphilic poly(ethylene oxide)-b-poly(aspartic
acid)(PEO-b-PAsp) copolymer, in which the hydrophilic polymer PEG was substituted with PEO [57].
In phase I clinical trials, the PEO-b-PAsp(DOX) formulation displayed higher anticancer activity than
free DOX, with a maximum tolerated dose of 67 mg/m2.
Pluronic is a triblock non-ionic PEO-PPO-PEO copolymer composed of poly(ethylene oxide) (PEO)
and poly(propylene oxide) (PPO) copolymers. A DOX formulation of the Pluronic PEO-PPO-PEO(DOX)
device, used as a P-glycoprotein inhibitor, showed a higher anticancer effect than free DOX in phase II
clinical trials [59]. In the Pluronic PEO-PPO-PEO(DOX) formulation, also known as SP1049C, DOX is
encapsulated by noncovalent bonds in the hydrophobic core of the micelles [82]. A study is ongoing
with patients with metastatic esophageal adenocarcinoma, gastric and stomach cancers in phase III
clinical trials [60]. Wang et al. obtained folate-targeted micelles composed of Pluronic copolymers, P105
and P105/L101, with loaded PTX in the core; they exhibited increased internalization that explained the
improved cytotoxicity of PTX to tumor cells in MCF-7 and MCF-7/ADR cells [83]. Chen et al. produced
atriblock co-delivery system for both DOX and PCT, which consists of conjugated Pluronic P105 with
DOX and encapsulated PCT into a hydrophobic core formed by P105-DOX and Pluronic F127. The
in vivo study of these Pluronic micelles applied in MCF7/ADR and KBv cell lines described eficient
tumor growth inhibition over 14 days at a 2:3 ratio of the drugs [84]. Moreover, Ma et al. studied the
application of pH-sensitive Pluronic F127-grafted chitosan for delivery of DOX together with PCT
in vivo, with a concentration ratio of 1:1 for DOX and PCT [85].
Recently, delivery of both DOX and PTX was studied using double-reacting nanoparticles built
of four polymers, such as poly(DL-lactide-co-glycolide) (PLGA), Pluronic F127 (PF127), chitosan,
and hyaluronic acid (HA). PLGA in combination with PF127 formed more stable and homogeneous
nanoparticles than PLGA or PF127 alone. HA was used as a targeting ligand in cancer stem cells to
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reduce drug resistance. The anticancer effect of these micelles co-loaded with both drugs was amplified
~500 times as compared to a simple mix of the two drugs [86].
Hu et al. have reported a multifunctional DDS with oxygen-generating theranostic nanoparticles (CDM
NPs) composed of the light-activated photosensitizer chlorin e6 (Ce6),DOX and colloidal manganese
dioxide (MnO2), assembled with the triblock poly(ε-caprolactone-co-lactide)-b-poly(ethylene
glycol)-b-poly(ε-caprolactone-co-lactide) PCLA-PEG-PCLA copolymer and used in breast cancer
therapy [61]. Combined chemotherapy with PDT could overcome the disadvantages of both therapies.
In addition to the well-known side effects of chemotherapy, the efficacy of PDT is dependent on
hypoxia in cancer cells. MnO2 in NPs reduces cancer hypoxia by catalyzing the decomposition of
endogenous hydrogen peroxide (H2O2), producing O2, andfurther, by the light-activation of chlorin
e6 (Ce6), it produces cytotoxic singlet oxygen (1O2), responsible for the killing of cancer cells. These
theranostic CDM NPs have high stability and biocompatibility, both in vitro and in vivo, indicating
that combined chemotherapy-PDT could attract great attention in future studies.
Nucleic acid therapeutics, such as siRNA, inhibit cancer-associated proteins or activate
cancer-suppressing pathways [76]. However, siRNA is very unstable in the systemic circulation
and poorly penetrates the cell membrane due to its high molecular weight, large negative charge and
enzyme-induced degradation. Therefore, combinations of chemotherapeutics with siRNA, complexed
by cationic polymeric copolymers, are under examination [24]. Cationic charged polymers, such as
poly(ethyleneimine) (PEI) and poly[2-(N,N-dimethylaminoethyl) methacrylate] (PDMAEMA) [29,30]
are suitable for complex binding siRNA by electrostatic interaction, preventing the degradation of siRNA
and enhancing its delivery across the cell membrane. Jin et al. have recently developed a promising
smart delivery system composed ofthe cationic deblock poly(ethyleneimine)-poly(lactic acid) (PEI-PLA)
copolymer, designed to deliver the drug PTX and the siRNA with a synergistic strategy in chemo- or
gene therapy in the treatment of non-small cell lung cancer (Table 1) [61]. This PTX formulation of NPs
increases the effect of the drugby siRNA inhibition of target proteins responsible for modulating cancer
cell metabolism and proliferation. This co-delivery system is a promising DDS with regard to high
drug loading, a longer half-life in the circulation, lower toxicity and an antiproliferative effect of PTX
on A549 cells. Cao et al. conjugated PEI with poly(ε-caprolactone) (PCL) through disulfide or ester
covalent linkages and DOX was loaded into PEI-PCL micelles by complex binding of the pro-apoptotic
protein siBcl-2 [33]. This DOX and Bcl-2 siRNA co-delivery system induced a 60% decrease in cell
viability 96 h after treatment in Bel7402 cell lines. When siScramble was used instead of siBcl-2,the
synergistic effect of the co-delivery of DOX and siBcl-2 was confirmed sincecell viability decreased by
only 40%. With further modification of the DOX+siBcl-2 nanocarrier by conjugation with folic acid, cell
viability decreased to 5%. Navarro et al. obtained the amphiphilic copolymer PEI conjugated with a
dioleoylphosphatidylethanolamine (DOPE) moiety with the delivery of P-glycoprotein siRNA (siP-gp)
and DOX that reversed the multidrug resistance in MCF7/ADR cells [34]. Another co-delivery system
for siRNA and chemotherapeutic DOX based on PEI with attached stearic acid as a hydrophobic
compartment (PEI-SA) was reported by Huang et al. [35]. The combination of DOX and VEGF siRNA
(siVEGF) co-delivered by PEI-SA micelles demonstrateda high in vivocancer growth inhibition effect in
Huh-7 cells. The amphiphilic structure of PEI-SA micelles supportsmultifunctional tasks for both genetic
and chemotherapeutic application. The hydrophilic shell modified with cationic charges of PEI-SA and
DNA or with anionic charges of siRNA are bound by electrostatic interaction, while the hydrophobic
core encapsulates the hydrophobic drug. Tang et al. also produced an amphiphilic copolymer based on
PEI and poly((1,4-butanediol)-diacrylate-b-5-hydroxyamylamine) (PDHA) [87]. When this copolymer,
polyethyleneimine-block-poly((1,4-butanediol)-diacrylate-b-5-hydroxyamylamine) (PEI-PDHA), was
self-assembled with PEG, it formed micelles that can co-load with three agents, siSnail, siTwist and the
drug PCT, exhibiting a 54.7-fold lower value of IC50 than that of free PCT.
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3.3. Polymer-Drug Conjugates in Cancer Therapy
Some PEG- and HPMA-drug conjugates are approved by the FDA and have found clinical
application due to their excellent properties, such as good solubility in water and many organic
solvents, high hydrophilicity, low toxicity and immunogenicity [88,89]. Several important polymer-drug
conjugates used in cancer therapy are summarized in Table 1.
PEG-based conjugates with the drugs camptothecin (CPT), camptothecin derivatives, SN38 and
irinotecan (C-11), used as topoisomerase I inhibitors, have progressed to phases I and II of clinical
studies [63–65]. These PEG-based conjugates carry the drugs in a lactone-active form bonded to PEG
through a glycine spacer. The PEG-CPT conjugate known as prothecan displayed low toxicity and
satisfactory tolerance in phase II studies in patients with adenocarcinoma of the stomach and the
gastroesophageal (GE)junction, although it confirmed significantly lower drug loading (1.7%) than other
polymer-drug conjugates [63]. PEG-SN38 (EZN-2208) and PEG-irinotecan (NKTR-102) conjugates were
synthesized by coupling a 4 arm PEG of 40 kDa with SN38 and irinotecan, respectively [66,67]. Irinotecan
is a derivative of SN38 containing an additional bis-piperidine group, which the PEG-irinotecan
conjugate releases at the targeting site of action, forming the active metabolite SN-38. However,
the PEG-SN38 conjugate provided a longer half-life of SN38 in the circulation and it is up to a
245-fold more efficient thanPEG-irinotecan conjugate in human cancer cell lines [67]. The anticancer
activity of PEG-SN38 was revealed in the therapy of breast, colorectal and pancreatic cancers. The
PEG-irinotecanconjugate had a half-life of 15 days compared to 4 h for free irinotecan [75]. The
PEG-irinotecan conjugate combined with cetuximab has entered into phase II study in the therapy of
ovarian, breast, colorectal and cervical cancers [68].
Copolymers of HPMA developed by Kopecek et al. [45] showed excellent hydrophilic properties
as biocompatible carriers for the delivery of drugs such DOX [69,70] and diaminocyclohexane
(DACH)-platinum (Table 1) [72–75]. Indeed, the developed HPMA-DOX and HPMA-DACH
platinum conjugates have drugs bonded to copolymers via an amidebond withthe tetrapeptide
glycine-phenylalanine-leucine-glycine (GFLG) and a pH-sensitive linker, respectively. The HPMA-DOX
conjugate (PK1, FCE28068), with DOX bound to the copolymer across the C-terminus of the glycine
moiety of linker GFLG, is decomposed by thiol-dependent lysosomal proteases [69,70]. It is the first
water-soluble drug conjugate under clinical assessment; it exhibited a 5-fold higher maximum tolerated
dose (MTD) of 320 mg/m2 than the free drug in a phase I study [69]. Clinical studies revealed its
anticancer efficacy in therapy of breast, colorectal and non-small cell lung cancers [70]. On the other
hand, the HPMA-(DACH)-platinum conjugate known as AP-5346, was developed [72–75]. It allows
controlled release of the drug in cancer cells by passive transport due to the small size of NPs (25 kDa)
with a longer half-life than the free (DACH)-platinum drug. Its anticancer activity was studied in
metastatic melanoma and ovarian cancer in a phase I study, and currently, with the name Prolindac, it
is undergoing phase II clinical trials [75]. Furthermore, based on molecular weight, chemical structure
and loading efficacy similar to the HPMA-DOX conjugate, the HPMA-DOX-galactosamine system
was developed; it possesses a conjugated galactosamine specified to target liver cancer cells [90–92].
This conjugate showed a 2-fold lower MTD (160 mg/m2) than HPMA-DOX, although in II phase
trials adose of 120 mg/m2 was evaluated because of its toxicity, which produces fatigue and leads to
neutropenia and mucositis in patients with metastatic liver cancer [92].Moreover, in phase I clinical
trials, HPMA-camptothecin (CPT) and -paclitaxel (PCX) conjugates with drugs bonded via an ester
bond through a linker, were also studied; they showed high toxicity due to the rapid ester hydrolysis
and drug release in vivo [71].
4. Stimuli-Responsive Polymer-Drug Conjugates
In the last two decades, many smart nanoplatforms have been designed by introducing stimuli
and targeting moieties into polymers of DDSs [93–97]. Some pH- and redox-responsive polymeric NPs
are described here as the most commonly used triggers in DDSs.
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Due to increased aerobic glycolysis, cancer cells have an acidic environment (pH 6.5–7.2), in
particular the intracellular organelles such as endosomes (pH 5–6) and lysosomes (pH 4–5) [93].
Therefore, many pH-responsive DDSs were designed by covalent attachment of the drug to the
polymeric NPs via an acid-labile bond. Bae et al. created diblock PEG-b-Pasp copolymers conjugated
with the drug adriamycin via a hydrazone bond, which can be easily cleaved under the acidic conditions
found in cancer cells, followed by rapid release of the drug and break-up of copolymers [93]. The
hydrazone bond of diverse nanoplatforms has been successfully applied to transport different anticancer
drugs such as DOX, PCX and cisplatin [8]. Guo et al. designed a multifunctional polymeric-drug
conjugate, FA-PEG-b-PCL-hyd-DOX, with a diblock PEG-PCL copolymer bound to DOX via a labile
hydrazone bond, and decorated with folic acid (FA) [8]. This DDS exerts cancer targeting ability
through the folate receptor (FR) interfering with endocytosis and pH-triggered drug release by the
breaking of the hydrazine bond under acidic conditions (Figure 3).
Figure 3. Mechanism of action of pH-responsive polymer nanoparticles(NPs) decorated with targeting
ligand folic acid (FA) and with the drug doxorubicin(DOX)bound via a hydrazone bond to diblock
copolymerPoly(ethylene glycol)-b-poly(ε-caprolactone)(PEG-PCL).
Xiong et al.recently reported on a multifunctional pH-responsive DDS composed of the diblock
PEO-b-PCL copolymer and the αvβ3 integrin-targeting ligand, RGD4C, on the micellar surface [94,95].
The delivery systems are based on RGD4C-PEO-b-P (CL-Hyd-DOX) micelles, including the hydrophobic
core (PCL), the drug DOX incorporated in the core via a pH-labile hydrazonebond, and a hydrophilic
shell (PEO) decorated with the targeting peptide ligand RGD4C. This multifunctional DDS had the
highest cytotoxic response in DOX-sensitive cancer cells, while the mitochondria-targeted NPs, created
as RGD4C-PEO-b-P (CL-Ami-DOX) micelles, conjugated with DOX via a stable amide bond (Ami),
showed the highest cytotoxic response in DOX-resistant cancer cells.
Due to the increased concentration of glutathione (GSH)in the cytosol and subcellular organelles,
there is a redox potential difference between the intra- and extracellular micro environments of normal
cellsthat is larger in cancer cells because of the 2- to 4-fold higher concentration of GSH [8]. The significant
increase in the intracellular redox potential was used as an internal stimulus for creating intelligent
DDSs by introducing a redox-sensitive functional group into the polymeric nanocarriers or reducible
linker. Similar to the previously described polymeric-drug conjugate, FA-PEG-b-PCL-hyd-DOX,
Shi et al. designed a redox-responsive FA-PECLSS-DOX nanocomplex by linking PEG and PCL
polymers via a redox-sensitive disulfide bond [96]. Thus, as a result of stimulation by the acidic and
reducing medium of cancer cells, GSH triggered DOX release by breaking the disulfide bond, with the
drug efficiently killing the cancer cells. Recent studies have also introduced a novel multifunctional
redox-responsive DDS based on the amphiphilic diblock PEG-b-PHEMA copolymer and covalently
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bounded PTX via a disulfide linker to poly(2-hydroxyethyl methacrylate)PHEMA in NPs (Figure 4) [97].
This biocompatible polymer-drug conjugate, PEG-b-P(HEMA-PTX),possessedglutathione-dependent
cytotoxicity, providing higher proliferation inhibition in glutathione monoester-pretreated HeLa cells
than in non-pretreated HeLa cells.
Figure 4. Mechanism of action of redox-responsive polymernanoparticles (NPs) with bonded
drug PTX via a disulfide linker to diblock copolymerPoly(ethylene glycol)-b-poly(2-hydroxyethyl
methacrylate)(PEG-b-PHEMA).
5. Conclusions
This article reviews recently obtained polymeric DDSs with applications in cancer therapy.
PEG and HMPA block copolymers, polymer-based drug conjugates and some multifunctional DDSs
decorated with stimuli and targeting moieties are summarized and their higher anticancer efficacy
compared to administered free drugs is highlighted. Diverse polymeric co-delivery systems have been
obtained showing high anticancer efficacy, especially in multidrug-resistant cancers. Polymeric block
micelles are ideal platforms for the co-delivery of combined drugs due to their multicompartment
structure. A single polymeric delivery system with two co-loaded drugs has a promising role in
cancer therapy because ofthe simultaneous targeting of different multidrug-resistance mechanisms.
Moreover, the ratio between two applied drugs can directly influence the efficacy of a co-delivery
system. Additionally, chemotherapy by the application of different polymeric micelles combined with
gene therapy has attracted considerable attention. Ligand-modified polymeric micelles improve the
anticancer effect of drugs because of receptor-mediated transport mechanisms. Efficient therapeutic
DDSs have been obtained by developing sophisticated polymeric micelles that can encapsulate various
bioactive molecules. Polymeric nanoplatforms have a promising role in cancer chemotherapy, although
moreclinical studies are necessaryin order to better understand their benefits and drawbacks.
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